Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Interval Compressed Four-Drug Regimen for Osteosarcoma
NCT03390946Phase 2Unknown
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, cisplatin, doxorubicin and ifosfamide in osteosarcoma (OS). Primary endpoint: Toxicity determined according to CTCAE. Status: unknown.
02
Drugs
methotrexatecisplatindoxorubicinifosfamide
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT03390946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03390946.